NEITHER CANCER NOR MYOSITIS ARE COMMON IN PATIENTS TESTING POSITIVE FOR TIF1. BY LINE IMMUNOBLOT ASSAY

被引：0
|
作者：
Troelnikov, Alexander [1 ,2 ]
Choo, Xin Jing [3 ]
Beroukas, Dimi [1 ]
Limaye, Vidya [3 ,4 ]
机构：
[1] SA Pathology, Immunopathol Dept, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Adelaide, SA, Australia
[3] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Dept Rheumatol, Adelaide, SA, Australia
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2023年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-42
引用
收藏
页码：455 / 455
页数：1
相关论文
共 50 条
  • [31] GSTM1 polymorphism in Oncotype DX assay can predict response to taxane-based neoadjuvant chemotherapy in ER-positive Chinese breast cancer patients
    Liao, N.
    Qian, X. K.
    Ren, C. Y.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S55 - S56
  • [32] Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario.
    Torres, Sofia
    Trudeau, Maureen E.
    Gandhi, Sonal
    Warner, Ellen
    Verma, Sunil
    Pritchard, Kathleen I.
    Petrella, Teresa M.
    Hew-Shue, Mark
    Chao, Calvin
    Eisen, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation
    Stolier, AJ
    Corsetti, RL
    AMERICAN SURGEON, 2005, 71 (12) : 1031 - 1033
  • [34] First-line treatment options for advanced gastric/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis
    Fan, Ling
    Lu, Ning
    Zhang, Lingmin
    Zhang, Jie
    Li, Jie
    Cui, Manli
    Zhang, Mingxin
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (06): : 2875 - 2883
  • [35] Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment
    Krajewski, Wojciech
    Poletajew, Slawomir
    Zdrojowy, Romuald
    Kolodziej, Anna
    SCANDINAVIAN JOURNAL OF UROLOGY, 2019, 53 (04) : 265 - 266
  • [36] Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study
    LeVasseur, Nathalie
    Sun, Julia
    Fenton, David
    Baxter, Simon
    Chan, Angela
    Roberts, Sarah
    Feng, Xiaolan
    Lohrisch, Caroline
    Gelmon, Karen
    Shenkier, Tamara
    Chia, Stephen K.
    CLINICAL BREAST CANCER, 2022, 22 (01) : E74 - E79
  • [37] An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States.
    Florea, Ana
    Garawin, Tamer
    Sangare, Laura
    Kelsh, Michael Anthony
    Lowe, Kimberly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
    Ferrero J.M.
    Etienne M.C.
    Formento J.L.
    Francoual M.
    Rostagno P.
    Peyrottes I.
    Ettore F.
    Teissier E.
    Leblanc-Talent P.
    Namer M.
    Milano G.
    British Journal of Cancer, 2000, 82 (1) : 171 - 177
  • [39] Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
    Ferrero, JM
    Etienne, MC
    Formento, JL
    Francoual, M
    Rostagno, P
    Peyrottes, I
    Ettore, F
    Teissier, E
    Leblanc-Talent, P
    Namer, M
    Milano, G
    BRITISH JOURNAL OF CANCER, 2000, 82 (01) : 171 - 177
  • [40] GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients
    Zhang, Guochun
    Qian, Xueke
    Ren, Chongyang
    Wen, Lingzhu
    Lyu, Haitong
    Liao, Ning
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (02) : 655 - 663
12345